INTERVENTION 1:	Intervention	0
Epoetin Beta	Intervention	1
Anemic breast cancer participants received epoetin beta (NeoRecormonÂ®) at a dose of 30000 International Units (IU) as subcutaneous (SC) injection once every week for a total of 12 weeks. Adjustments in the dose were implemented based on the participant's blood hemoglobin levels.	Intervention	2
breast cancer	DOID:1612	7-20
week	UO:0000034	157-161
week	UO:0000034	180-184
blood	UBERON:0000178	255-260
hemoglobin	CHEBI:35143	261-271
Inclusion Criteria:	Eligibility	0
Adult female participants with histological diagnosis of breast cancer	Eligibility	1
adult	EFO:0001272	0-5
female	PATO:0000383	6-12
breast cancer	DOID:1612	57-70
Any type of chemotherapy planned for greater than or equal to (>/=) 9 weeks	Eligibility	2
Hemoglobin level less than (<) 11 grams per deciliter (g/dL)	Eligibility	3
hemoglobin	CHEBI:35143	0-10
Participants able to receive iron supplement, if necessary	Eligibility	4
Exclusion Criteria:	Eligibility	5
Known or suspected contraindications to epoetin beta	Eligibility	6
Pregnancy or lactation period	Eligibility	7
lactation	GO:0007595	13-22
Diagnosis of anemia only due to iron-deficiency	Eligibility	8
anemia	HP:0001903,DOID:2355	13-19
Diagnosis of thalasemic syndromes	Eligibility	9
Epilepsy and/or cerebral metastasis	Eligibility	10
epilepsy	DOID:1826	0-8
Blood transfusion or treatment with any erythropoietic factor within 4 weeks before study start	Eligibility	11
blood	UBERON:0000178	0-5
Outcome Measurement:	Results	0
Percentage of Participants With Response to Treatment Based on Hemoglobin Levels	Results	1
hemoglobin	CHEBI:35143	63-73
Response was defined as increase of hemoglobin levels by at least 2 grams per deciliter (g/dL) as compared to baseline or the achievement of hemoglobin level of 12 g/dL after 12 weeks of treatment in the absence of red blood cells transfusion.	Results	2
increase	BAO:0001251	24-32
hemoglobin	CHEBI:35143	36-46
hemoglobin	CHEBI:35143	141-151
blood	UBERON:0000178	219-224
Time frame: Week 12	Results	3
time	PATO:0000165	0-4
week	UO:0000034	12-16
Results 1:	Results	4
Arm/Group Title: Epoetin Beta	Results	5
Arm/Group Description: Anemic breast cancer participants received epoetin beta (NeoRecormon  ) at a dose of 30000 International Units (IU) as subcutaneous (SC) injection once every week for a total of 12 weeks. Adjustments in the dose were implemented based on the participant's blood hemoglobin levels.	Results	6
breast cancer	DOID:1612	30-43
week	UO:0000034	181-185
week	UO:0000034	204-208
blood	UBERON:0000178	279-284
hemoglobin	CHEBI:35143	285-295
Overall Number of Participants Analyzed: 197	Results	7
Measure Type: Number	Results	8
Unit of Measure: percentage of participants  46.2        (38.2 to 54.3)	Results	9
Adverse Events 1:	Adverse Events	0
Total: 17/197 (8.63%)	Adverse Events	1
Neutropenia * 1/197 (0.51%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	0-11
Pancytopenia * 1/197 (0.51%)	Adverse Events	3
pancytopenia	HP:0001876,DOID:12450	0-12
Disease progression * 2/197 (1.02%)	Adverse Events	4
disease	DOID:4,OGMS:0000031	0-7
Fatigue * 1/197 (0.51%)	Adverse Events	5
fatigue	HP:0012378	0-7
General physical health deterioration * 1/197 (0.51%)	Adverse Events	6
Contrast media reaction * 1/197 (0.51%)	Adverse Events	7
Cachexia * 1/197 (0.51%)	Adverse Events	8
cachexia	HP:0004326	0-8
Bone pain * 1/197 (0.51%)	Adverse Events	9
bone pain	HP:0002653	0-9
Metastases to central nervous system * 1/197 (0.51%)	Adverse Events	10
central nervous system	UBERON:0001017	14-36
